These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30337703)

  • 21. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers.
    Shuhaibar M; Walsh C; Lindsay F; Lee N; Walsh P; O'Gorman P; Boran G; McLoughlin R; Qasim A; Breslin N; Ryan B; O'Connor H; O'Morain C
    Ir J Med Sci; 2011 Mar; 180(1):103-8. PubMed ID: 20953981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.
    Hillyer GC; Schmitt KM; Freedberg DE; Kramer RA; Su Y; Rosenberg RM; Neugut AI
    Am J Prev Med; 2014 Aug; 47(2):182-7. PubMed ID: 24951037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
    Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
    Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
    Brenner H; Hoffmeister M; Birkner B; Stock C
    Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of stratifying by family history in colorectal cancer screening programs.
    Goede SL; Rabeneck L; Lansdorp-Vogelaar I; Zauber AG; Paszat LF; Hoch JS; Yong JH; van Hees F; Tinmouth J; van Ballegooijen M
    Int J Cancer; 2015 Sep; 137(5):1119-27. PubMed ID: 25663135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
    Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
    Bretagne JF; Carlo A; Piette C; Rousseau C; Cosson M; Lièvre A
    Br J Cancer; 2021 Nov; 125(11):1494-1502. PubMed ID: 34511603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study.
    Denis B; Gendre I; Perrin P
    J Med Screen; 2015 Jun; 22(2):76-82. PubMed ID: 25576338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States.
    Singal AG; Corley DA; Kamineni A; Garcia M; Zheng Y; Doria-Rose PV; Quinn VP; Jensen CD; Chubak J; Tiro J; Doubeni CA; Ghai NR; Skinner CS; Wernli K; Halm EA
    Am J Gastroenterol; 2018 May; 113(5):746-754. PubMed ID: 29487413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of follow-up colonoscopy after positive FOBT in an organized colorectal cancer screening program is associated with modifiable health care practices.
    Correia A; Rabeneck L; Baxter NN; Paszat LF; Sutradhar R; Yun L; Tinmouth J
    Prev Med; 2015 Jul; 76():115-22. PubMed ID: 25895843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.
    Shapiro JA; Bobo JK; Church TR; Rex DK; Chovnick G; Thompson TD; Zauber AG; Lieberman D; Levin TR; Joseph DA; Nadel MR
    Am J Gastroenterol; 2017 Nov; 112(11):1728-1735. PubMed ID: 29016558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fecal occult blood test in colorectal cancer screening.
    Li JN; Yuan SY
    J Dig Dis; 2019 Feb; 20(2):62-64. PubMed ID: 30714325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
    Meklin J; SyrjÄnen K; Eskelinen M
    Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interval Colorectal Cancers following Guaiac Fecal Occult Blood Testing in the Ontario ColonCancerCheck Program.
    Paszat L; Sutradhar R; Tinmouth J; Baxter N; Rabeneck L
    Can J Gastroenterol Hepatol; 2016; 2016():4768728. PubMed ID: 27446842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.